Elijah F. Edmondson

This study identifies SUV420H1 as a driver in HPV-negative HNSCC, showing its role in proliferation, invasion, and immune evasion, and suggests targeting it to improve immunotherapy response.

This study identifies co-inhibition of XPO1 and EIF4A1 as a therapeutic strategy for mCRPC, showing synergistic antitumor effects at reduced drug doses.

This study identifies E-cadherin/YAP-dependent pyruvate carboxylase expression as a metabolic driver of breast cancer progression and metastasis, with therapeutic implications for epithelial TNBC.

A β-galactose-cleavable linker reduces kidney toxicity, enhances tumor targeting and therapeutic efficacy in radiopharmaceutical therapy.

This study identifies NF1/RASA1/TP53 co-mutations and MEK signaling as key drivers of sinonasal tumorigenesis through in vivo CRISPR screening and drug response testing.

This study shows that tRNA acetylation regulates stress signaling in mammals by affecting ribosome function and interacting with the Gcn2 kinase.

The paper identifies spatial interactions between NOS2, COX2, and T-effector cells in ER- breast cancer, linking these patterns to poor patient outcomes and suggesting potential therapeutic strategies.

This study identifies NOS2 and COX2 as key spatial targets in ER- breast cancer that influence immune phenotypes and clinical outcomes through spatial analysis of tumor microenvironments.